SGLT2 inhibitors have recently been recommended as an essential element of therapy for patients with heart failure and reduced ejection fraction (HFrEF) due to their favorable effects on mortality, clinical events, and quality of life [36]. The gene discussed is SLC5A2; the disease is heart failure.